Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non–Small-Cell Lung Cancer
- 1 November 2022
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (11) , e1874-e1884
Abstract
PURPOSE: Next-generation sequencing (NGS) is a crucial component of evaluation of patients with newly diagnosed metastatic non–small-cell lung cancer (NSCLC) to determine appropriate first-line treatment. This quality improvement project aimed to reduce time to NGS results in patients with metastatic NSCLC. METHODS: We reviewed electronic medical records of patients with newly diagnosed, untreated metastatic NSCLC from December 2018 to August 2021 and determined the number of days from pathologic diagnosis to NGS results. We reviewed process maps for oncology, pathology, the Division of Research, and a NGS vendor to determine factors leading to preventable delays. Since November 2020, we created an automated, electronic weekly report to provide earlier identification of new pathologic diagnoses in patients with metastatic NSCLC. On June 2021, we worked with our NGS vendors to expand days of the week to accept specimens. RESULTS: Our interventions reduced the median time from pathologic diagnosis to NGS results from 24 (standard deviation [SD] 9) to 16 (SD 6) days. The median time from biopsy results to NGS order was reduced from 7 days to 1 day. The time from the specimen being sent from pathology to the NGS vendor was a median of 6 days in both cohorts. The total time from pathologic diagnosis to appropriate treatment was reduced from 33 (SD 18) to 22 (SD 8) days. CONCLUSION: NGS processing in a community setting can be complex. Using a systems focused approach to quality improvement is crucial in identifying the greatest barriers in an organization. We found that delays in time to NGS results can be reduced by improved communication and workflows among departments.Keywords
This publication has 24 references indexed in Scilit:
- The Kaiser Permanente Northern California Adult Member Health SurveyThe Permanente Journal, 2016
- Typical Time to Treatment of Patients With Lung Cancer in a Multisite, US-Based StudyJournal of Oncology Practice, 2016
- Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing ApproachesClinical Cancer Research, 2015
- Teams and Teamwork During a Cancer Diagnosis: Interdependency Within and Between TeamsJournal of Oncology Practice, 2015
- Reviewing Cancer Care Team EffectivenessJournal of Oncology Practice, 2015
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Benchmarking of Mutation Diagnostics in Clinical Lung Cancer SpecimensPLOS ONE, 2011
- Complementary and alternative therapy use before and after breast cancer diagnosis: the Pathways StudyBreast Cancer Research and Treatment, 2009
- Timeliness of Care in Veterans With Non-small Cell Lung CancerChest, 2008